Shares of Momenta Pharmaceuticals (Nasdaq:MNTA) were gapping down Monday morning with an open price 21% lower than Friday's closing price. The stock closed at $17.01 yesterday and opened today's trading at $13.44.
NEW YORK ( TheStreet) -- Shares of Momenta Pharmaceuticals (Nasdaq: MNTA) were gapping down Monday morning with an open price 21% lower than Friday's closing price. The stock closed at $17.01 Friday and opened today's trading at $13.44.
The average volume for Momenta has been 411,000 shares per day over the past 30 days. Momenta has a market cap of $836.2 million and is part of the health care sector and drugs industry. Shares are down 6.7% year to date as of the close of trading on Friday. Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural characterization, process engineering, and biologic systems analysis of complex molecules. These complex molecules include polysaccharides, polypeptides, and proteins and antibodies. The company has a P/E ratio of seven, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Momenta as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. You can view the full Momenta Ratings Report. Get more investment ideas from our investment research center.